Cannabis Law Report

DECEMBER 23, 2021

Findings in The Pharmaceutical Cannabis Report: 2nd Edition include: The author estimates the market size for the three most widely used cannabinoid pharmaceuticals (Epidiolex, Sativex, Dronabinol) to be worth just under €900 million as of 2021, growing to €1.8 billion by 2025. The current medical cannabis market is bursting with innovation.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. RADNOR, Pa.–(BUSINESS Data Highlights.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

The Cannigma

MARCH 7, 2022

When CBN was studied without barbiturates (prescription sedative medications typically used for epilepsy), the combination of CBN and THC produced greater sedation together than either cannabinoid alone. What can the current clinical trials tell us?

THC 140

THC Clinical Trials Sleep Cannabinoids 140

TheAnswerPage

JUNE 19, 2021

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.

Clinical Trials 40

Clinical Trials Epilepsy Treatment CBD 40

Cannabis Law Report

SEPTEMBER 6, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. during 2021-2026. The global medical cannabis market exhibited strong growth during 2015-2020. 4 Introduction.

Chronic Pain 66

Chronic Pain Research and Development Clinical Trials Epilepsy 66

TheAnswerPage

JULY 13, 2021

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 45

Clinical Trials Epilepsy Pharmaceutical Treatment 45

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — SciSparc Ltd. OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Cannabis Law Report

AUGUST 19, 2021

Such products will generate sales of £690 million ($856 million, 811 million euros) in 2021, according to the Association for the Cannabinoid Industry (ACI). Faced with booming sales, professor Sagnik Bhattacharyya, who researches psychotic and substance abuse disorders at King’s College London, says clinical trials are needed.

Cannabinoids 105

Cannabinoids Seed-To-Sale Clinical Trials CBD 105

Cannabis Law Report

SEPTEMBER 9, 2021

DUBLIN–(BUSINESS WIRE)–The “Global Legal Cannabis Market 2021-2028” report has been added to ResearchAndMarkets.com’s offering. Global Legal Cannabis Industry: Number of Clinical Trials, By Region. The global legal cannabis market size is expected to reach USD 91.5 over the forecast period.

Recreational 73

Recreational Hemp THC Legalization 73

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. For instance, as of June 2021, InMed Pharmaceuticals, Inc.,

Cannabinoids 40

Cannabinoids Clinical Trials Research and Development Supply Chain 40

TheAnswerPage

MAY 25, 2022

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.

Clinical Trials 40

Clinical Trials Epilepsy Treatment CBD 40

Cannabis Law Report

DECEMBER 1, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Date: December 2, 2021. Dates: December 8-9, 2021. Registration: Click here.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Cannabis Law Report

NOVEMBER 25, 2021

Epilepsy Treatment. This study is, of course, well-vetted, and has offered plenty of hope to sufferers of epilepsy. According to various clinical trials, individuals who took CBD before speaking publicly in front of a big audience were able to remain calm and deliver their remarks with relative ease.

CBD 52

CBD Clinical Trials Epilepsy Chronic Pain 52

Veriheal

MARCH 23, 2023

The report states that the revision is an essential move for ensuring the legal use of cannabis-derived epilepsy drug Epidiolex , which is currently being reviewed as part of a series of clinical trials in Japan. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products.

Legalization 82

Legalization Marijuana Clinical Trials Seed-To-Sale 82

Healer

DECEMBER 17, 2021

November 5, 2021. Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Epilepsy & behavior case reports 9 (2018): 10. Hospital Pharmacy (2021): 0018578720985438. Journal of clinical psychopharmacology 41.5

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We On July 30, 2021, Virpax announced the appointment of Gerald W. On August 17, 2021, Virpax announced that it had received FDA response and guidance on AnQlar.

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. MAPS Public Benefit Corporation will coordinate trial design with Medicines and Healthcare products Regulatory Agency to create a road map for early patient access in the UK.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

OCTOBER 5, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. The Company’s presentation will be available for viewing that day at 10:10 a.m.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Media 40

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. 19 vaccine candidate in Mexico.

Pharmaceutical 40

Pharmaceutical Clinical Trials Business Chronic Pain 40

Cannabis Law Report

OCTOBER 19, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. MyMD Chief Scientific Officer Adam Kaplin, M.D.,

Pharmaceutical 40

Pharmaceutical Therapy Clinical Trials Chronic Pain 40

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. royalty on all future net sales.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain CBD 40

Cannabis Law Report

OCTOBER 1, 2021

Mack will present an overview of Virpax and take part in a fireside chat moderated by Noble Capital Markets senior equity research analyst, Gregory Aurand at the Pain Management Virtual Investor Forum on Thursday, October 7, 2021 at 9:00 a.m. Eastern time. www.youtube.com/channelchek. About Virpax Pharmaceuticals.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials Chronic Pain 40

Canna Care Docs

DECEMBER 16, 2020

The New Year is fast approaching, and if you’re not feeling entirely hopeful about 2021, you’re certainly not alone. Could medical cannabis help you find the “new you” in 2021? Enough is enough. But you deserve a silver lining for your health, and it’s within reach. Chronic pain.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

Cannabis Law Report

FEBRUARY 3, 2022

million in 2021, and is projected to reach USD 176,005.5 million by 2030 at a CAGR of 23.9%, 2021-2030. CBD oils have various health benefits in treating medical disorders like epilepsy, anxiety, cancer, acne, diabetes, and others. 2564 (2021). Clinical Trials of Cannabis Are Still on Going. Legalization.

Indica 40

Indica Oil Legalization Clinical Trials 40

Cannabis Law Report

OCTOBER 26, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Cannabis Law Report

SEPTEMBER 1, 2019

The Victorian and New South Wales Governments had both begun clinical trials of cannabis products for children with severe epilepsy and for palliative care, respectively. The clinical trials and the standard of production could lead the world.”. Source: [link].

Clinical Trials 53

Clinical Trials Research and Development Medicine Cultivation 53

Cannabis Law Report

DECEMBER 28, 2021

.–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I Mack, Chairman and CEO of Virpax. to conduct this study in Canada.

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 23, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Chronic Pain 40

The Cannigma

AUGUST 26, 2021

In addition, as of early 2021 , it is legal to purchase CBD oil over the counter in Australia. These products can only be accessed through the Special Access Scheme by an authorized healthcare practitioner, or as part of a clinical trial, according to the Office of Drug Control. Qualifying conditions for medical marijuana.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Cannabis Law Report

JUNE 1, 2021

Company remains on track for potential approval of Vicineum™ in the US in August 2021. Hoff and Dr. McLin and four additional new employees between June 1, 2021 and June 14, 2021 pursuant to which an aggregate of up to 1,995,000 shares of Sesen Bio common stock will be purchasable upon vesting. CAMBRIDGE, Mass.–(BUSINESS

Research and Development 51

Research and Development Treatment Pharmaceutical Patients 51

Healer

DECEMBER 17, 2021

November 5, 2021. Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Epilepsy & behavior case reports 9 (2018): 10. [4] Hospital Pharmacy (2021): 0018578720985438. [5] 2021): 525-533. [8]

CBD 52

CBD THC Conditions Medicine 52

Puff Puff Post

DECEMBER 28, 2018

Initially, he refused their requests due to insufficient data, however the evidence shown by a recent study done in Israel on CBD managing epilepsy was enough to sway him in the other direction. CBD Oil For Autism: The Method and Results of Dr. Aran’s Study.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

NOVEMBER 10, 2021

In October 2021, Virpax announced that a $1.87 Also, the NIH engaged Battelle to conduct Dose Range Finding Studies, with the first study in rats being completed on October 7 th , 2021. A Dose Range Finding Study in dogs will start on November 10, 2021. A Dose Range Finding Study in dogs will start on November 10, 2021.

Research and Development 40

Research and Development Chronic Pain Pharmaceutical Clinical Trials 40